Dr. Rocio Salas-Whalen

Knowing this and understanding this, you move away of anxiety. putting the pressure on the patient, right? You move away of being a one participant in this equation. It goes more into a team, what you can do for the patient and educating the patient. It becomes a team. Let's talk about, as an example, diabetes, type 2 diabetes.

We know it's a chronic multifactorial disease, but we have no trouble prescribing and treating medications for it, right? It's widely accepted from the patient side, from the physician side. Let's talk about hypertension. Same thing, right? We know that lifestyle can help it or make it worse. but that is not causing the disease.

We know it's a chronic multifactorial disease, but we have no trouble prescribing and treating medications for it, right? It's widely accepted from the patient side, from the physician side. Let's talk about hypertension. Same thing, right? We know that lifestyle can help it or make it worse. but that is not causing the disease.

We know it's a chronic multifactorial disease, but we have no trouble prescribing and treating medications for it, right? It's widely accepted from the patient side, from the physician side. Let's talk about hypertension. Same thing, right? We know that lifestyle can help it or make it worse. but that is not causing the disease.

Therefore, we feel comfortable treating it and the patients accepting treatment. And when we provide treatment for type two diabetes, hypertension, high cholesterol, we always talk about eating healthier and exercising, but it doesn't replace the treatment. So if we see obesity as a disease, we can act the same way.

Therefore, we feel comfortable treating it and the patients accepting treatment. And when we provide treatment for type two diabetes, hypertension, high cholesterol, we always talk about eating healthier and exercising, but it doesn't replace the treatment. So if we see obesity as a disease, we can act the same way.

Therefore, we feel comfortable treating it and the patients accepting treatment. And when we provide treatment for type two diabetes, hypertension, high cholesterol, we always talk about eating healthier and exercising, but it doesn't replace the treatment. So if we see obesity as a disease, we can act the same way.

Understand and support the patient and their lifestyle, but also provide a medical treatment.

Understand and support the patient and their lifestyle, but also provide a medical treatment.

Understand and support the patient and their lifestyle, but also provide a medical treatment.

But also there's other things like medications that patients may take for certain particular disease that can promote waking, right? There's a lot of antidepressants that can promote waking, blood pressure medications that can promote waking, right? And many times there's no other option for the patient. And this can also lead to obesity.

But also there's other things like medications that patients may take for certain particular disease that can promote waking, right? There's a lot of antidepressants that can promote waking, blood pressure medications that can promote waking, right? And many times there's no other option for the patient. And this can also lead to obesity.

But also there's other things like medications that patients may take for certain particular disease that can promote waking, right? There's a lot of antidepressants that can promote waking, blood pressure medications that can promote waking, right? And many times there's no other option for the patient. And this can also lead to obesity.

The first FDA-approved GLP-1 was in 2005.

The first FDA-approved GLP-1 was in 2005.

The first FDA-approved GLP-1 was in 2005.

Yes. The FDA name, it was by Eli Lilly. It was called Bayera. And this was twice a day subcutaneous injection. So it was a daily, twice a day injection that patients had to do. Okay. And the first indication was for type 2 diabetes because GLP-1 is a hormone.

Yes. The FDA name, it was by Eli Lilly. It was called Bayera. And this was twice a day subcutaneous injection. So it was a daily, twice a day injection that patients had to do. Okay. And the first indication was for type 2 diabetes because GLP-1 is a hormone.

Yes. The FDA name, it was by Eli Lilly. It was called Bayera. And this was twice a day subcutaneous injection. So it was a daily, twice a day injection that patients had to do. Okay. And the first indication was for type 2 diabetes because GLP-1 is a hormone.

Glucagon-like peptide. And it's a peptide or a hormone.